Logo

American Heart Association

  24
  0


Final ID: MP922

Polygenic Risk Score for Abdominal Aortic Aneurysm in Patients with Cardiometabolic Disease: Analysis of 40,000 Patients from 3 TIMI Trials

Abstract Body (Do not enter title and authors here): Background
Abdominal aortic aneurysm (AAA) is a common and potentially fatal condition when rupture occurs. Current US guidelines recommend screening by ultrasound in men aged 65–75 with a smoking history. However, AAA remains underdiagnosed using these limited clinical criteria, underscoring the need to explore additional risk factors. We evaluated whether the addition of a polygenic risk score (PRS) for AAA helps identify individuals at higher risk among patients with established cardiometabolic disease.

Methods
A genetic analysis was performed by pooling individual patient-level data from 3 TIMI trials (FOURIER, ENGAGE-AF and PEGASUS). AAA events were reported by investigators as adverse events, and blinded study physicians independently reviewed and confirmed all cases. We utilized a recently validated AAA PRS (Nat Genet, 2023) and assessed its association with AAA using Cox proportional hazard models adjusted for age, sex, smoking, history of ASCVD, HTN, hyperlipidemia, DM, trial and ancestry (PC1–5). PRS was analyzed continuously (per 1-SD) and categorically (high [top 20%], intermediate [middle 60%], low [bottom 20%]).

Results
A total of 39,960 patients were included (median f/u 2.6 years). Individuals in higher PRS categories had a higher rate of AAA events over time (Figure 1A). Even after adjusting for clinical risk factors, a 1-SD higher PRS was independently associated with a 54% higher risk of AAA (HR-adj 1.54 [95% CI 1.35–1.76], p<0.001). Compared with low PRS, an intermediate PRS was associated with a 2-fold risk (HR-adj 2.03 [1.23–3.34], p<0.001), and a high PRS with a 3-fold risk (HR-adj 3.12 [1.82–5.36], p<0.001). The magnitude of risk conferred by a high PRS was comparable to traditional clinical risk factors (Figure 1B).

Coclusion
In patients with cardiometabolic disease, an AAA PRS was independently associated with risk of AAA events, with a magnitude of risk on par with traditional clinical risk factors.
  • Lai, Yi-pin  ( TIMI Study Group , Boston , Massachusetts , United States )
  • Sabatine, Marc  ( TIMI Study Group , Boston , Massachusetts , United States )
  • Ruff, Christian  ( TIMI Study Group , Boston , Massachusetts , United States )
  • Marston, Nicholas  ( TIMI Study Group , Boston , Massachusetts , United States )
  • Al Said, Samer  ( TIMI Study Group , Boston , Massachusetts , United States )
  • Melloni, Giorgio  ( TIMI Study Group , Boston , Massachusetts , United States )
  • Kamanu, Frederick  ( TIMI Study Group , Boston , Massachusetts , United States )
  • Giugliano, Robert  ( TIMI Study Group , Boston , Massachusetts , United States )
  • Antman, Elliott  ( TIMI Study Group , Boston , Massachusetts , United States )
  • Braunwald, Eugene  ( TIMI Study Group , Boston , Massachusetts , United States )
  • Ellinor, Patrick  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Bonaca, Marc  ( CPC Clinical Research , Aurora , Colorado , United States )
  • Author Disclosures:
    Yi-Pin Lai: DO NOT have relevant financial relationships | Marc Sabatine: DO have relevant financial relationships ; Research Funding (PI or named investigator):Abbott; Amgen; Anthos Therapeutics, Inc.; AstraZeneca; Boehringer Ingelheim; Daiichi-Sankyo; Ionis; Marea; Merck; Novartis; Pfizer; Saghmos Therapeutics; Verve Therapeutics:Active (exists now) ; Consultant:Amgen; AMPEL BioSolutions; Anthos Therapeutics, Inc.; AstraZeneca; Beren Therapeutics; Boehringer Ingelheim; CCRN; Dr. Reddy’s Laboratories; General Medicines; Merck; NATF; Novo Nordisk; Precision BioSciences.:Active (exists now) | Christian Ruff: DO NOT have relevant financial relationships | Nicholas Marston: DO have relevant financial relationships ; Research Funding (PI or named investigator):Ionis:Active (exists now) ; Other (please indicate in the box next to the company name):Janssen (DSMB):Active (exists now) ; Advisor:Radence:Active (exists now) ; Advisor:New Amsterdam:Past (completed) ; Advisor:Ionis:Expected (by end of conference) ; Advisor:Amgen:Past (completed) ; Speaker:Amgen:Past (completed) ; Research Funding (PI or named investigator):Amgen:Active (exists now) | Samer Al Said: DO NOT have relevant financial relationships | Giorgio Melloni: No Answer | Frederick Kamanu: DO NOT have relevant financial relationships | Robert Giugliano: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Speaker:Novartis:Past (completed) ; Advisor:Inventiva:Active (exists now) ; Speaker:Dr. Reddy's:Past (completed) ; Speaker:SUMMEET:Past (completed) ; Speaker:Shakeheart:Past (completed) ; Speaker:Big Sky:Past (completed) ; Speaker:Daiichi Sankyo:Active (exists now) ; Consultant:Daiichi Sankyo:Active (exists now) ; Speaker:Amgen:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Research Funding (PI or named investigator):Ionis:Active (exists now) | Elliott Antman: DO have relevant financial relationships ; Research Funding (PI or named investigator):Daiichi Sankyo:Active (exists now) | Eugene Braunwald: No Answer | Patrick Ellinor: DO have relevant financial relationships ; Research Funding (PI or named investigator):Bayer AG:Active (exists now) ; Consultant:Bayer AG:Past (completed) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):BMS:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) | Marc Bonaca: DO have relevant financial relationships ; Employee:CPC Clinical Research:Active (exists now) ; Consultant:Prairie Education and Research Cooperative, Prothena Biosciences Limited, Regeneron Pharmaceuticals, Inc., Regio Biosciences, Inc., Sanofi-Aventis Groupe, Silence Therapeutics PLC, Smith & Nephew plc, Stealth BioTherapeutics Inc., VarmX, Virta Health Corporation.:Active (exists now) ; Consultant:Medimmune Ltd., Merck & Affiliates, Nectero Medical Inc., Novartis Pharmaceuticals Corp., Novo Nordisk, Inc., Osiris Therapeutics Inc., Pfizer Inc., PhaseBio Pharmaceuticals, Inc.:Active (exists now) ; Consultant:Exicon Consulting Pvt. Ltd., Faraday Pharmaceuticals, Inc., Foresee Pharmaceuticals Co. Ltd., Fortress Biotech, Inc., HDL Therapeutics Inc., HeartFlow Inc., Hummingbird Bioscience, Insmed Inc., Ionis Pharmaceuticals, Janssen and Affiliates, Kowa Research Institute, Inc., Lexicon Pharmaceuticals, Inc.:Active (exists now) ; Consultant:Bayer and Affiliates, Bristol-Meyers Squibb Company, Cambrian Biopharma, Inc., Cardiol Therapeutics Inc., CellResearch Corp., Cleerly Inc., Cook Regentec LLC, CSL Behring LLC, Eidos Therapeutics, Inc., EP Trading Co. Ltd., Epizon Pharma, Inc., Esperion Therapeutics, Inc., Everly Well, Inc.:Active (exists now) ; Consultant:Abbott Laboratories, Agios Pharmaceuticals, Inc., Alexion Pharma, Alnylam Pharmaceuticals, Inc., Amgen Inc., Angionetics, Inc., Anthos Therapeutics, Array BioPharma, Inc., AstraZeneca and Affiliates, Atentiv LLC, Audentes Therapeutics, Inc.:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Vascular Genetics, Genomics, and Risk Scores

Saturday, 11/08/2025 , 03:15PM - 04:30PM

Moderated Digital Poster Session

More abstracts on this topic:


Clickable Extracellular Vesicles for Localized Abdominal Aortic Aneurysm Repair

Marini Ande, Otto Ellen, Li Bo, Weinbaum Justin, Ren Xi, Campbell Phil, Curci John, Vorp David

C-C Chemokine Receptor Type 2 and Matrix Metalloproteinases Molecular Interaction in Rat Abdominal Aortic Aneurysm

Zaghloul Mohamed, Elizondo Benedetto Santiago, Arif Batool, Heo Gyu Seong, Luehmann Hannah, Liu Yongjian, Gropler Robert, Sadeghi Mehran, Zayed Mohamed

More abstracts from these authors:
A Polygenic Score to Identify Risk of Incident Stroke and Benefit from Primary Prevention Statin Therapy

Mcclintick Daniel, Kamanu Frederick, Melloni Giorgio, Sabatine Marc, Ruff Christian, Ridker Paul, Chasman Daniel, Marston Nicholas

Polygenic Risk Score Associated With Kidney Disease Progression In Patients With Cardiometabolic Risk Factors

Park Jun, Marston Nicholas, Kamanu Frederick, Melloni Giorgio, Lai Yi-pin, Giugliano Robert, Scirica Benjamin, Wiviott Stephen, Sabatine Marc, Ruff Christian

You have to be authorized to contact abstract author. Please, Login
Not Available